A growing body of evidence suggests that psychedelic drugs may be useful in treating various mental health conditions. However, many challenges remain in defining their clinical benefits and overcoming the complex regulatory obstacles to their use. The September 2023 issue of Journal of Psychiatric Practice presents a research review and update on therapeutic use of psychedelics--focusing on the use of psilocybin for treatment of depression. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer. The article is titled “Psychedelics, With a Focus on Psilocybin: Issues for the Clinician.”
Login Or Register To Read Full Story